Microbubbles ||| S:0 E:12 ||| NNP
:  ||| S:12 E:14 ||| :
current  ||| S:14 E:22 ||| JJ
state  ||| S:22 E:28 ||| NN
and  ||| S:28 E:32 ||| CC
future  ||| S:32 E:39 ||| JJ
prospects  ||| S:39 E:49 ||| NNS
Contrast-enhanced  ||| S:49 E:67 ||| JJ
ultrasound  ||| S:67 E:78 ||| NN
( ||| S:78 E:79 ||| -LRB-
CEUS ||| S:79 E:83 ||| NNP
)  ||| S:83 E:85 ||| -RRB-
represents  ||| S:85 E:96 ||| VBZ
one  ||| S:96 E:100 ||| CD
of  ||| S:100 E:103 ||| IN
the  ||| S:103 E:107 ||| DT
most  ||| S:107 E:112 ||| RBS
interesting  ||| S:112 E:124 ||| JJ
applications  ||| S:124 E:137 ||| NNS
of  ||| S:137 E:140 ||| IN
traditional  ||| S:140 E:152 ||| JJ
medical  ||| S:152 E:160 ||| JJ
sonography ||| S:160 E:170 ||| NN
.  ||| S:170 E:172 ||| .
Ultrasound  ||| S:172 E:183 ||| JJ
contrast  ||| S:183 E:192 ||| NN
agents  ||| S:192 E:199 ||| NNS
are  ||| S:199 E:203 ||| VBP
classified  ||| S:203 E:214 ||| VBN
into  ||| S:214 E:219 ||| IN
first-  ||| S:219 E:226 ||| JJ
and  ||| S:226 E:230 ||| CC
second-generation  ||| S:230 E:248 ||| JJ
agents  ||| S:248 E:255 ||| NNS
depending  ||| S:255 E:265 ||| VBG
on  ||| S:265 E:268 ||| IN
the  ||| S:268 E:272 ||| DT
gas  ||| S:272 E:276 ||| NN
( ||| S:276 E:277 ||| -LRB-
nitrogen ||| S:277 E:285 ||| UH
,  ||| S:285 E:287 ||| ,
perfluorocarbon  ||| S:287 E:303 ||| NN
or  ||| S:303 E:306 ||| CC
sulfur  ||| S:306 E:313 ||| JJ
hexafluoride ||| S:313 E:325 ||| NN
)  ||| S:325 E:327 ||| -RRB-
in  ||| S:327 E:330 ||| IN
the  ||| S:330 E:334 ||| DT
microbubbles ||| S:334 E:346 ||| NN
.  ||| S:346 E:348 ||| .
Both  ||| S:348 E:353 ||| DT
generations  ||| S:353 E:365 ||| NNS
are  ||| S:365 E:369 ||| VBP
characterized  ||| S:369 E:383 ||| VBN
by  ||| S:383 E:386 ||| IN
an  ||| S:386 E:389 ||| DT
excellent  ||| S:389 E:399 ||| JJ
safety  ||| S:399 E:406 ||| NN
profile ||| S:406 E:413 ||| NN
,  ||| S:413 E:415 ||| ,
with  ||| S:415 E:420 ||| IN
low  ||| S:420 E:424 ||| JJ
hepatic  ||| S:424 E:432 ||| NN
and  ||| S:432 E:436 ||| CC
renal  ||| S:436 E:442 ||| JJ
toxicity  ||| S:442 E:451 ||| NN
and  ||| S:451 E:455 ||| CC
rare  ||| S:455 E:460 ||| JJ
central  ||| S:460 E:468 ||| JJ
nervous  ||| S:468 E:476 ||| JJ
system  ||| S:476 E:483 ||| NN
reactions ||| S:483 E:492 ||| NNS
.  ||| S:492 E:494 ||| .
The  ||| S:494 E:498 ||| DT
respiratory  ||| S:498 E:510 ||| NN
and  ||| S:510 E:514 ||| CC
hepatic  ||| S:514 E:522 ||| JJ
elimination  ||| S:522 E:534 ||| NN
of  ||| S:534 E:537 ||| IN
the  ||| S:537 E:541 ||| DT
gases  ||| S:541 E:547 ||| NN
explains  ||| S:547 E:556 ||| VBZ
the  ||| S:556 E:560 ||| DT
low  ||| S:560 E:564 ||| JJ
nephrotoxicity ||| S:564 E:578 ||| NN
.  ||| S:578 E:580 ||| .
CEUS  ||| S:580 E:585 ||| NNP
has  ||| S:585 E:589 ||| VBZ
been  ||| S:589 E:594 ||| VBN
successfully  ||| S:594 E:607 ||| RB
employed  ||| S:607 E:616 ||| VBN
in  ||| S:616 E:619 ||| IN
drug  ||| S:619 E:624 ||| NN
and  ||| S:624 E:628 ||| CC
gene  ||| S:628 E:633 ||| NN
delivery ||| S:633 E:641 ||| NN
.  ||| S:641 E:643 ||| .
Indeed ||| S:643 E:649 ||| RB
,  ||| S:649 E:651 ||| ,
new  ||| S:651 E:655 ||| JJ
molecules  ||| S:655 E:665 ||| NNS
such  ||| S:665 E:670 ||| JJ
as  ||| S:670 E:673 ||| IN
liposomes ||| S:673 E:682 ||| NN
,  ||| S:682 E:684 ||| ,
micelles  ||| S:684 E:693 ||| NN
and  ||| S:693 E:697 ||| CC
perfluorocarbon  ||| S:697 E:713 ||| JJ
nanoparticles  ||| S:713 E:727 ||| NNS
have  ||| S:727 E:732 ||| VBP
been  ||| S:732 E:737 ||| VBN
recently  ||| S:737 E:746 ||| RB
proposed  ||| S:746 E:755 ||| VBN
as  ||| S:755 E:758 ||| IN
ultrasound  ||| S:758 E:769 ||| JJ
contrast  ||| S:769 E:778 ||| NN
agents ||| S:778 E:784 ||| NNS
.  ||| S:784 E:786 ||| .
Possible  ||| S:786 E:795 ||| JJ
future  ||| S:795 E:802 ||| JJ
applications  ||| S:802 E:815 ||| NNS
of  ||| S:815 E:818 ||| IN
liposomes  ||| S:818 E:828 ||| NNS
are  ||| S:828 E:832 ||| VBP
the  ||| S:832 E:836 ||| DT
treatment  ||| S:836 E:846 ||| NN
of  ||| S:846 E:849 ||| IN
hypertension  ||| S:849 E:862 ||| JJ
complications  ||| S:862 E:876 ||| NNS
( ||| S:876 E:877 ||| -LRB-
given  ||| S:877 E:883 ||| VBN
the  ||| S:883 E:887 ||| DT
possibility  ||| S:887 E:899 ||| NN
to  ||| S:899 E:902 ||| TO
fill  ||| S:902 E:907 ||| VB
them  ||| S:907 E:912 ||| PRP
with  ||| S:912 E:917 ||| IN
nitric  ||| S:917 E:924 ||| JJ
oxide ||| S:924 E:929 ||| NN
) ||| S:929 E:930 ||| -RRB-
,  ||| S:930 E:932 ||| ,
the  ||| S:932 E:936 ||| DT
treatment  ||| S:936 E:946 ||| NN
of  ||| S:946 E:949 ||| IN
cerebral  ||| S:949 E:958 ||| JJ
disease  ||| S:958 E:966 ||| NN
with  ||| S:966 E:971 ||| IN
xenon ||| S:971 E:976 ||| NN
,  ||| S:976 E:978 ||| ,
and  ||| S:978 E:982 ||| CC
the  ||| S:982 E:986 ||| DT
treatment  ||| S:986 E:996 ||| NN
of  ||| S:996 E:999 ||| IN
breast  ||| S:999 E:1006 ||| NN
and  ||| S:1006 E:1010 ||| CC
liver  ||| S:1010 E:1016 ||| JJ
cancer  ||| S:1016 E:1023 ||| NN
with  ||| S:1023 E:1028 ||| IN
doxorubicin ||| S:1028 E:1039 ||| NN
.  ||| S:1039 E:1041 ||| .
Micelles  ||| S:1041 E:1050 ||| NNS
have  ||| S:1050 E:1055 ||| VBP
been  ||| S:1055 E:1060 ||| VBN
demonstrated  ||| S:1060 E:1073 ||| VBN
to  ||| S:1073 E:1076 ||| TO
be  ||| S:1076 E:1079 ||| VB
effective  ||| S:1079 E:1089 ||| JJ
in  ||| S:1089 E:1092 ||| IN
cancer  ||| S:1092 E:1099 ||| NN
treatment  ||| S:1099 E:1109 ||| NN
as  ||| S:1109 E:1112 ||| IN
well ||| S:1112 E:1116 ||| RB
.  ||| S:1116 E:1118 ||| .
Finally ||| S:1118 E:1125 ||| RB
,  ||| S:1125 E:1127 ||| ,
perfluorocarbon  ||| S:1127 E:1143 ||| JJ
nanoparticles  ||| S:1143 E:1157 ||| NN
can  ||| S:1157 E:1161 ||| MD
be  ||| S:1161 E:1164 ||| VB
used  ||| S:1164 E:1169 ||| VBN
in  ||| S:1169 E:1172 ||| IN
oncological  ||| S:1172 E:1184 ||| JJ
settings  ||| S:1184 E:1193 ||| NNS
and  ||| S:1193 E:1197 ||| CC
in  ||| S:1197 E:1200 ||| IN
pancreatic  ||| S:1200 E:1211 ||| JJ
islet  ||| S:1211 E:1217 ||| JJ
transplantation  ||| S:1217 E:1233 ||| NN
in  ||| S:1233 E:1236 ||| IN
patients  ||| S:1236 E:1245 ||| NNS
with  ||| S:1245 E:1250 ||| IN
type  ||| S:1250 E:1255 ||| NN
I  ||| S:1255 E:1257 ||| PRP
diabetes ||| S:1257 E:1265 ||| VBD
.  ||| S:1265 E:1267 ||| .
